{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:47:37Z","timestamp":1765601257758,"version":"3.48.0"},"reference-count":19,"publisher":"Japan Surgical Society","issue":"1","funder":[{"name":"Kochi Organization for Medical Reformation and Renewal grants"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2025]]},"DOI":"10.70352\/scrj.cr.25-0539","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T22:09:21Z","timestamp":1765577361000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Conversion Surgery Following Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma with Para-Aortic Lymph Node Metastases: A Case of Complete Hepatic Response and Lymphatic Resistance"],"prefix":"10.70352","volume":"11","author":[{"given":"Sunao","family":"Uemura","sequence":"first","affiliation":[{"name":"Department of Gastroenterological Surgery, Kochi Health Sciences Center, Kochi, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Tokumaru","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Kochi Health Sciences Center, Kochi, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuta","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Kochi Health Sciences Center, Kochi, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyasu","family":"Tabuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Kochi Health Sciences Center, Kochi, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Kochi Health Sciences Center, Kochi, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Yoshimatsu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kochi Health Sciences Center, Kochi, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kochi Health Sciences Center, Kochi, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kochi Health Sciences Center, Kochi, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Okabayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Kochi Health Sciences Center, Kochi, Kochi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229\u201363.","DOI":"10.3322\/caac.21834"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. J Clin Oncol 2024; 42: 1830\u201350.","DOI":"10.1200\/JCO.23.02745"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894\u2013905.","DOI":"10.1056\/NEJMoa1915745"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid 2022; 1: EVIDoa2100070.","DOI":"10.1056\/EVIDoa2100070"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Arita J, Ichida A, Nagata R, et al. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors. J Hepatobiliary Pancreat Sci 2022; 29: 732\u201340.","DOI":"10.1002\/jhbp.1135"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Yau T, Galle PR, Decaens T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet 2025; 405: 1851\u201364.","DOI":"10.1016\/S0140-6736(25)00403-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Vitale I, Shema E, Loi S, et al. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med 2021; 27: 212\u201324.","DOI":"10.1038\/s41591-021-01233-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) P\u00e9rez-Gonz\u00e1lez A, B\u00e9vant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat Cancer 2023; 4: 1063\u201382.","DOI":"10.1038\/s43018-023-00595-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sayaman RW, Saad M, Thorsson V, et al. Germline genetic contribution to the immune landscape of cancer. Immunity 2021; 54: 367\u201386.e8.","DOI":"10.1016\/j.immuni.2021.01.011"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol 2016; 9: 74.","DOI":"10.1186\/s13045-016-0307-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Park MY, Kim KR, Park HS, et al. Expression of the serum response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition. Int J Oncol 2007; 31: 1309\u201315.","DOI":"10.3892\/ijo.31.6.1309"},{"key":"12","unstructured":"12) Furuhashi S, Morita Y, Matsumoto A, et al. Tenascin C in pancreatic cancer-associated fibroblasts enhances epithelial mesenchymal transition and is associated with resistance to immune checkpoint inhibitor. Am J Cancer Res 2023; 13: 5641\u201355."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Jeong H, Koh J, Kim S, et al. Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer. Br J Cancer 2024; 131: 23\u201336.","DOI":"10.1038\/s41416-024-02698-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Chan ASL, Zhu H, Narita M, et al. Titration of RAS alters senescent state and influences tumour initiation. Nature 2024; 633: 678\u201385.","DOI":"10.1038\/s41586-024-07797-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg 2023; 158: 410\u201320.","DOI":"10.1001\/jamasurg.2022.7989"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ye LY, Chen W, Bai XL, et al. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res 2016; 76: 818\u201330.","DOI":"10.1158\/0008-5472.CAN-15-0977"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Dituri F, Mancarella S, Cigliano A, et al. TGF-\u03b2 as multifaceted orchestrator in HCC progression: signaling, EMT, immune microenvironment, and novel therapeutic perspectives. Semin Liver Dis 2019; 39: 53\u201369.","DOI":"10.1055\/s-0038-1676121"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ward FJ, Kennedy PT, Al-Fatyan F, et al. CTLA-4-two pathways to anti-tumour immunity? Immunother Adv 2025; 5: ltaf008.","DOI":"10.1093\/immadv\/ltaf008"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Naserkhaki R, Shokouhian B, Tahamtani Y, et al. Revisiting treatment strategies: addressing epithelial-to-mesenchymal transition-induced resistance in hepatocellular carcinoma. BME Front 2025; 6: 0144.","DOI":"10.34133\/bmef.0144"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0539\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:42:53Z","timestamp":1765600973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0539\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0539","relation":{},"ISSN":["2198-7793"],"issn-type":[{"type":"electronic","value":"2198-7793"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"cr.25-0539"}}